Medtronic plc, a global leader in healthcare technology, and DASI Simulations, a leader in AI-driven predictive modeling and digital-twin technology, today announced a strategic partnership to enhance access to DASI technology to optimize outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the United States.

This program marks a significant step forward in both Medtronic’s and DASI’s mission to deliver innovative, patient-specific care. By integrating DASI Simulations’ advanced AI-based predictive modeling and digital twin technology into the TAVR workflow, clinicians will gain access to independent and device-agnostic actionable insights that support more precise, individualized treatment decisions for patients living with aortic stenosis.

“Effective pre-case planning is essential to achieving optimal outcomes in TAVR,” said Matthew Summers, MD, interventional cardiologist at Sentara Heart Hospital. “Integrating DASI’s predictive modeling into our workflow has allowed us to better visualize anatomy, anticipate risks, and tailor valve decisions to each patient. It’s helped us focus on individual factors like annular rupture, coronary occlusion, and paravalvular leak, while also planning for future reinterventions. As TAVR complexity grows, it becomes increasingly important to have tools that support truly personalized decision-making. This includes making informed choices between surgical aortic valve replacement and TAVR, as well as which TAVR valve, to ensure the best possible care.”
“Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide,” said Teri Sirset, MS, founder, president, and chief executive officer of DASI Simulations. “Together, we’re demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care. This collaboration reflects the growing demand for data-driven solutions that empower heart teams to deliver more confident, personalized treatment decisions.”

DASI’s FDA-cleared platform leverages real patient computerized tomography (CT) anatomies and retrospective outcomes to simulate multiple transcatheter heart valve (THV) deployment scenarios. Using these data-driven reports – rooted in independent device-agnostic, patient-specific predictive modeling – will help mitigate human error, predict complications, and optimize long-term management for structural heart patients.

Industry Partnerships Homepage